Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 36Carcinoma, Non-Small-Cell Lung 36Multiple Myeloma 26Breast Neoplasms 26Glioma 23Carcinoma, Renal Cell 22Pancreatic Neoplasms 21Melanoma 21Glioblastoma 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Ovarian Neoplasms 19Urinary Bladder Neoplasms 18Lymphoma 18Colorectal Neoplasms 18Triple Negative Breast Neoplasms 15Oropharyngeal Neoplasms 15Mouth Neoplasms 15Brain Neoplasms 15Fallopian Tube Neoplasms 13Carcinoma, Hepatocellular 13Carcinoma 13Laryngeal Neoplasms 12Astrocytoma 12Lymphoma, Follicular 11Leukemia, Myeloid, Acute 11Sarcoma 10Neuroblastoma 10

Interventions

ipatasertib 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡